Ocular Toxicity of Mirvetuximab

Cornea. 2019 Feb;38(2):229-232. doi: 10.1097/ICO.0000000000001805.


Purpose: To report the clinical features and outcomes of corneal toxicity following mirvetuximab soravtansine therapy.

Methods: Five patients who were treated with mirvetuximab soravtansine were evaluated in our hospital for ocular symptoms during a period of 5 months between December 2017 and April 2018. A complete ophthalmologic examination, including anterior segment infrared reflectance (AS-IR) and anterior segment optical coherence tomography (AS-OCT), was performed.

Results: All 5 patients were female (average age, 62.4 ± 5.5 years) and being treated for advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Both eyes were involved in each case. Patients complained of blurred vision (n = 5), ocular pain (n = 2), tearing (n = 5), foreign-body sensation (n = 4), and photophobia (n = 4). Slit-lamp examination demonstrated fine corneal subepithelial opacities, mainly involving the corneal periphery migrating toward the center. AS-IR revealed the presence of hyporeflective dots on the cornea, suggesting that they were cystic. AS-OCT confirmed the subepithelial location of lesions. In all patients, the cornea cleared, and visual acuity recovered fully with a short course of topical steroids and lubricants.

Conclusions: Mirvetuximab soravtansine therapy can cause transient corneal toxicity. A short course of topical steroids can reduce the patient symptoms.

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Corneal Diseases / chemically induced*
  • Female
  • Humans
  • Immunoconjugates / adverse effects*
  • Maytansine / adverse effects
  • Maytansine / analogs & derivatives*
  • Middle Aged
  • Vision Disorders / chemically induced*


  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic
  • Immunoconjugates
  • Maytansine
  • mirvetuximab soravtansine